RxDoctor Payments Data

Bonnie Cameron

Optometrist · Montgomery, TXNPI 1346438298

Payments from drug & device makers

$12,383in general payments, 2019–2025

Across 128 payments — averaging $96.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$7K
  • Johnson & Johnson Vision Care, Inc.$2K
  • Alcon$939
  • Bausch & Lomb Americas Inc.$456
  • AbbVie$404
  • Oyster Point Pharma, Inc.$388
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$2402%
  • Speaking & faculty fees$5004%
  • Food & beverage$11,64394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,383 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$56,537
Medicare patients
289
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf33$29,855
TyrvayaVarenicline Tartrate11$6,944
LumiganBimatoprost11$6,564
Prednisolone Acetate67$1,723
Latanoprost111$1,444
Timolol Maleate55$682
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$404
ErythromycinErythromycin Base22$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo$456$29,85533 claims
Oyster Point Pharma, Inc.Tyrvaya$388$6,94411 claims
AbbVieLumigan$404$6,56411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Montgomery

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →